Alnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.75) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same quarter last year, the company earned ($1.68) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, analysts expect Alnylam Pharmaceuticals to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alnylam Pharmaceuticals Trading Down 1.6 %

Shares of ALNY stock opened at $143.80 on Thursday. Alnylam Pharmaceuticals has a 12 month low of $143.50 and a 12 month high of $218.88. The stock has a market cap of $18.11 billion, a P/E ratio of -40.39 and a beta of 0.39. The company has a 50 day simple moving average of $150.77 and a two-hundred day simple moving average of $166.28.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent research reports. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Citigroup cut their price objective on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research note on Friday, February 16th. BMO Capital Markets restated an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Nine equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.